The FDA has recently approved multi-dose pens (KwikPens) for Zepbound and Mounjaro
GLP-1s and Obesity Coverage: Differing Perspectives for Employers and Health Plans Posted on August 21, 2025 A Snippet From Our GLP-1 Spotlight Webinar Key Points Employers tend to view obesity as a chronic condition, while health plans lean slightly toward viewing obesity as a lifestyle condition
Now that the supply has stabilized, the FDA has removed GLP-1 therapies from the national shortage list, suggesting these medications should be easier to access
It offers a more budget-friendly option for patients or practices looking to control costs without sacrificing efficacy
[DOI] [PMC free article] [PubMed] [Google Scholar] 9.Bukowski K, Kciuk M, Kontek R
Some peptides occur naturally, while others are synthesized using recombinant DNA technology to mirror the bodys own signaling compounds